CHANGES IN CLINICAL AND BIOCHEMICAL BLOOD PARAMETERS CAUSED BY SHORTENED TB TREATMENT COURSE CONTAINING BPaMZ

Aim: to study changes in the parameters of clinical blood and urine tests, as well as biochemical blood tests in patients with pulmonary TB on treatment containing bedaquiline, pretomanid, moxifloxacin, and pyrazinamide (BPаMZ). Materials and methods. We studied 7 patients with drug-resistant pulmonary TB on a 6-month treatment course containing BPaMZ. We analyzed the changes in blood and urine parameters, as well as the changes in biochemical blood parameters. Results. We established that administration of BPaMZ did not affect hemoglobin levels, and caused leukocytopenia, eosinophilia, or thrombocytopenia in single cases. We observed elevated levels of monocytes at early stages of treatment (two weeks, one or two months), but later the number of cases with monocytosis decreased. The number of cases with ketonuria,erythrocyturia, bacteriuria, leukocyturia, or nitrituria also increased at early stages of treatment. However, the number of such cases decreased at further stages. We observed proteinuria, albuminuria, bilirubinuria, and urobilinogenuria in single cases. The most significant change in biochemical profiles was the elevated level of uric acid, which was detected in 6 of 7 cases at early stages of treatment and in more than half of the patients until the end of the observation. Pathological changes in the levels of potassium, chlorine, glucose, creatinine, albumin, as well as the markers of liver damage (ALT, AST, and total bilirubin) were observed in single cases. Conclusion. The administration of BPaMZ causes changes in clinical blood and urine parameters, as well as biochemical blood parameters. Mostly, these are mild changes observed at early stages of treatment. By the 6th month of treatment the incidence of these changes decreases.